Effects of Tanreqing injection combined with Budesonide Formoterol inhalation in treatment of patients with acute exacerbation of chronic obstructive pulmonary disease
Objective:To observe effects of Tanreqing injection combined with Budesonide Formoterol inhalation in treatment of patients with acute exacerbation of chronic obstructive pulmonary disease(COPD).Methods:A prospective study was conducted on 96 patients with acute exacerbation of COPD admitted to this hospital from 2022 to 2023.According to the random number table method,they were divided into control group and observation group,48 cases in each group.The control group was treated with Budesonide Formoterol inhalation,while the observation group was treated with Tanreqing injection on the basis of that of the control group.The clinical efficacy,the scores of TCM syndromes(main symptoms,secondary symptoms),the levels of lung function[forced vital capacity(FVC),forced expiratory volume in one second(FEV1),peak expiratory flow rate(PEF)],the levels of inflammatory factors[amyloid A(SAA),interleukin-6(IL-6)],and the levels of oxidative stress indexes[superoxide dismutase(SOD)],before and after the treatment,and the incidence of adverse reactions were compared between the two groups.Results:The total effective rate of the observation group was 93.75%(45/48),which was higher than 72.92%(35/48)of the control group,and the difference was statistically significant(P<0.05).After the treatment,the scores of TCM syndromes such as main symptoms and secondary symptoms in the two groups were lower than those before the treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).The levels of FVC,FEV1 and PEF in the two groups were higher than those before the treatment,those in the observation group were higher than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the SOD levels of the two groups were higher than those before the treatment,and that in the observation group was higher than that in the control group;the levels of SAA and IL-6 in the two groups were lower than those before the treatment,and those in the observation group were lower than those in the control group;and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Tanreqing injection combined with Budesonide Formoterol inhalation in the treatment of the patients with acute exacerbation of COPD can improve the total effective rate,the lung function index levels and the SOD levels,and reduce the TCM syndrome scores and the inflammatory factor index levels.Moreover,it is superior to simple Budesonide Formoterol inhalation treatment.
万方数据
维普
